Figure 2. Asprosin neutralization corrects hyperglycemia, hyperphagia, and hypertriglyceridemia in a dose-dependent manner.

Baseline blood glucose (measured 4 hr post-treatment), plasma insulin and triglyceride (TG; at 24 hr post-treatment) levels, cumulative food intake, body weight change (measured 24 hr post-treatment), were measured upon injecting increasing dose of anti-asprosin mAb in 16-week-old male DIO (diet-induced obesity) mice, n = 5/group. The doses tested were 15.63, 31.25, 62.5, 125, and 250 µg/mouse, corresponding to 0.4, 0.85, 1.64, 3.28, and 6.88 mg/kg. Half maximal inhibitor concentration (IC₅₀) was determined using a four- and three-parameter non-linear variable slope curve. r (Romere et al., 2016) value determined the goodness of fit (Figure 2—source data 1).